melatonin has been researched along with Psychoses in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results from this trial will examine whether melatonin has a role in withdrawing long-term benzodiazepine administration in schizophrenia patients." | 9.15 | Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. ( Baandrup, L; Fagerlund, B; Glenthoj, BY; Gluud, C; Hansen, JL; Jennum, P; Lublin, H; Oranje, B; Winkel, P, 2011) |
| " Since depression is associated with diminished melatonin secretion, the high incidence of TD in patients with history of depression may be linked to diminished secretory activity of the pineal melatonin." | 7.68 | Mood-dependent fluctuations in the severity of tardive dyskinesia and psoriasis vulgaris in a patient with schizoaffective disorder: possible role of melatonin. ( Pardeshi, R; Sandyk, R, 1990) |
| " Reduced benzodiazepine dosage at the 24-week follow-up was associated with a significantly decreased proportion of stage 2 sleep." | 6.82 | Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. ( Baandrup, L; Glenthøj, BY; Jennum, PJ, 2016) |
| "The results from this trial will examine whether melatonin has a role in withdrawing long-term benzodiazepine administration in schizophrenia patients." | 5.15 | Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. ( Baandrup, L; Fagerlund, B; Glenthoj, BY; Gluud, C; Hansen, JL; Jennum, P; Lublin, H; Oranje, B; Winkel, P, 2011) |
| " Since depression is associated with diminished melatonin secretion, the high incidence of TD in patients with history of depression may be linked to diminished secretory activity of the pineal melatonin." | 3.68 | Mood-dependent fluctuations in the severity of tardive dyskinesia and psoriasis vulgaris in a patient with schizoaffective disorder: possible role of melatonin. ( Pardeshi, R; Sandyk, R, 1990) |
| " Reduced benzodiazepine dosage at the 24-week follow-up was associated with a significantly decreased proportion of stage 2 sleep." | 2.82 | Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. ( Baandrup, L; Glenthøj, BY; Jennum, PJ, 2016) |
| "Distinguishing circadian timing from other sleep phenotypes will allow adaptation for dosage of time-directed intervention, useful in stabilizing circadian timekeeping physiology and potentially reducing the multisystemic disruption in mental health disorders." | 1.91 | Phenotypic divergence in sleep and circadian cycles linked by affective state and environmental risk related to psychosis. ( Alexander, I; Cosgrave, J; Foster, RG; Middleton, B; Porcheret, K; Purple, RJ; Wulff, K, 2023) |
| "In melatonin treated rats, prefrontal tissue malondialdehyde and protein carbonyl levels were decreased significantly in comparison with MK-801 group (p < 0." | 1.40 | Potential role of some oxidant/antioxidant status parameters in prefrontal cortex of rat brain in an experimental psychosis model and the protective effects of melatonin. ( Akyol, O; Kus, I; Ozyurt, B; Ozyurt, H; Sarsilmaz, M; Songur, A, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Purple, RJ | 2 |
| Cosgrave, J | 2 |
| Alexander, I | 2 |
| Middleton, B | 2 |
| Foster, RG | 2 |
| Porcheret, K | 2 |
| Wulff, K | 2 |
| Nordholm, D | 1 |
| Jensen, MA | 1 |
| Glenthøj, LB | 1 |
| Kristensen, TD | 1 |
| Wenneberg, C | 1 |
| Garde, AH | 1 |
| Nordentoft, M | 1 |
| Ozyurt, H | 1 |
| Ozyurt, B | 1 |
| Sarsilmaz, M | 1 |
| Kus, I | 1 |
| Songur, A | 1 |
| Akyol, O | 1 |
| Inanir, S | 1 |
| Copoglu, US | 1 |
| Kokacya, H | 1 |
| Dokuyucu, R | 1 |
| Erbas, O | 1 |
| Inanir, A | 1 |
| Baandrup, L | 2 |
| Glenthøj, BY | 1 |
| Jennum, PJ | 1 |
| Lamont, EW | 1 |
| Coutu, DL | 1 |
| Cermakian, N | 1 |
| Boivin, DB | 1 |
| Kolesnikov, DB | 1 |
| Rapoport, SI | 1 |
| Voznesenskaia, LA | 1 |
| Fagerlund, B | 1 |
| Jennum, P | 1 |
| Lublin, H | 1 |
| Hansen, JL | 1 |
| Winkel, P | 1 |
| Gluud, C | 1 |
| Oranje, B | 1 |
| Glenthoj, BY | 1 |
| Miyazaki, T | 1 |
| Kuwano, H | 1 |
| Kato, H | 1 |
| Ando, H | 1 |
| Kimura, H | 1 |
| Inose, T | 1 |
| Ohno, T | 1 |
| Suzuki, M | 1 |
| Nakajima, M | 1 |
| Manda, R | 1 |
| Fukuchi, M | 1 |
| Tsukada, K | 1 |
| Tharandt, L | 1 |
| Reinwein, D | 1 |
| Wahlund, B | 1 |
| Sääf, J | 1 |
| Grahn, H | 1 |
| Wetterberg, L | 1 |
| Katz, G | 2 |
| Durst, R | 3 |
| Barel, YC | 1 |
| Knobler, HY | 2 |
| Campbell, KM | 1 |
| Wade, D | 1 |
| Ross, LW | 1 |
| Meyer, GG | 1 |
| Mullen, PE | 1 |
| Silman, RE | 1 |
| Robinson, S | 1 |
| Rosca, P | 1 |
| Shai, U | 1 |
| Ghinea, C | 1 |
| Schmidt, U | 1 |
| Nir, I | 1 |
| Sandyk, R | 1 |
| Pardeshi, R | 1 |
| Johnston, VS | 1 |
| Bradley, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia[NCT03075657] | Phase 4 | 120 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial[NCT01431092] | Phase 4 | 86 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study Prior to a Larger Randomized Controlled Trial[NCT02200172] | Phase 2 | 60 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
4 reviews available for melatonin and Psychoses
| Article | Year |
|---|---|
Circadian rhythms and clock genes in psychotic disorders.
Topics: Animals; Bipolar Disorder; Circadian Rhythm; CLOCK Proteins; Glycogen Synthase Kinase 3; Humans; Lit | 2010 |
[Psychic disorders and gastrointestinal pathology. Part 2].
Topics: Gastrointestinal Diseases; Humans; Melatonin; Psychotic Disorders; Risk Factors | 2010 |
[Melatonin, a clinically important hormone?].
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Central Nervous System; Circadian Rhythm; Female; Humans | 1983 |
Molecular pharmacology of hallucinogens.
Topics: Amphetamine; Animals; Avoidance Learning; Brain; Conditioning, Operant; Emotions; Hallucinogens; Hum | 1968 |
2 trials available for melatonin and Psychoses
12 other studies available for melatonin and Psychoses
| Article | Year |
|---|---|
Phenotypic divergence in sleep and circadian cycles linked by affective state and environmental risk related to psychosis.
Topics: Circadian Rhythm; Humans; Melatonin; Phenotype; Psychotic Disorders; Sleep | 2023 |
Phenotypic divergence in sleep and circadian cycles linked by affective state and environmental risk related to psychosis.
Topics: Circadian Rhythm; Humans; Melatonin; Phenotype; Psychotic Disorders; Sleep | 2023 |
Phenotypic divergence in sleep and circadian cycles linked by affective state and environmental risk related to psychosis.
Topics: Circadian Rhythm; Humans; Melatonin; Phenotype; Psychotic Disorders; Sleep | 2023 |
Phenotypic divergence in sleep and circadian cycles linked by affective state and environmental risk related to psychosis.
Topics: Circadian Rhythm; Humans; Melatonin; Phenotype; Psychotic Disorders; Sleep | 2023 |
Sleep disturbances and the association with attenuated psychotic symptoms in individuals at ultra high-risk of psychosis.
Topics: Adolescent; Adult; Humans; Melatonin; Psychiatric Status Rating Scales; Psychotic Disorders; Risk Fa | 2023 |
Potential role of some oxidant/antioxidant status parameters in prefrontal cortex of rat brain in an experimental psychosis model and the protective effects of melatonin.
Topics: Animals; Antioxidants; Disease Models, Animal; Dizocilpine Maleate; Glutathione Peroxidase; Male; Ma | 2014 |
Agomelatine Protection in an LPS-Induced Psychosis-Relevant Behavior Model.
Topics: Acetamides; Animals; Brain; Lipopolysaccharides; Male; Malondialdehyde; Melatonin; Psychotic Disorde | 2015 |
Correlation between serum melatonin circadian rhythm and intensive care unit psychosis after thoracic esophagectomy.
Topics: Adult; Aged; Circadian Rhythm; Esophageal Neoplasms; Esophagectomy; Female; Humans; Intensive Care U | 2003 |
Diagnostic subgrouping of depressed patients by principal component analysis and visualized pattern recognition.
Topics: Adult; Biomarkers; Bipolar Disorder; Blood Platelets; Depressive Disorder; Dexamethasone; Female; Fo | 1998 |
De novo jet-lag psychosis.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Clopenthixol; Female; Humans; Jet Lag Syndrome; Ma | 1999 |
Exogenous melatonin, jet lag, and psychosis: preliminary case results.
Topics: Adult; Antioxidants; Female; Humans; Jet Lag Syndrome; Male; Melatonin; Middle Aged; Psychotic Disor | 2001 |
Pigmentation and musculoskeletal abnormalities in an aged state hospital population.
Topics: Adult; Aged; Bone Diseases; Dihydroxyphenylalanine; Female; Humans; Male; Melanins; Melatonin; Menta | 1977 |
The pineal and psychiatry: a review.
Topics: Animals; Behavior, Animal; Brain; Electroencephalography; Humans; Melatonin; Pineal Gland; Psychotic | 1977 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Mood-dependent fluctuations in the severity of tardive dyskinesia and psoriasis vulgaris in a patient with schizoaffective disorder: possible role of melatonin.
Topics: Adult; Depression; Dyskinesia, Drug-Induced; Female; Humans; Melatonin; Psoriasis; Psychotic Disorde | 1990 |